The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000638336p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
23/04/2026
Date registered
Help: Date registered
26/05/2026
Date last updated
Help: Date last updated
26/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Dose finding Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ZE74-0282 in Select JAK2 V617F Mutated Hematologic Disorders
Scientific title
A Dose finding Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ZE74-0282 in Select JAK2 V617F Mutated Hematologic Disorders
Additional trial identifiers [1] 316982 0
ZE74-0282-0002
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Myeloproliferative Neoplasms (MPNs) 341443 0
Condition category
Condition code
Cancer 337506 337506 0 0
Myeloma
Blood 337591 337591 0 0
Haematological diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a Phase 1, open-label, multicenter, dose escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of ZE74-0282 in patients JAK2 V617F mutated hematologic diagnosis with prior therapy or who declined them. Up to 60 participants are planned to be enrolled in this study.

The study will be run in 2 parts: Part 1 will be dose escalation and determination of maximum tolerated dose (MTD) in up to 5 cohorts and Part 2 will be dose expansion into 2 cohorts.

Part 1: Thirty participants will receive escalating doses of ZE74-0282 powder administered as a suspension orally once daily or twice daily in continuous 28-day treatment cycles with a dose range of 150 mg for Cohort 1 up to 600 mg for Cohort 4 until the MTD or intolerable dose level is reached. If prior healthy volunteer dosing data demonstrate that once daily or twice daily dosing may be relevant, a twice daily dosing cohort at 75 mg twice daily can be pursued concurrently. It is anticipated that a decision to do once daily or twice daily dosing will occur after completion of Cohort 1. Progression to subsequent cohort dosing level will be decided by the safety review committee after reviewing data from Cycle 1 treatment from 3 enrolled patients in initial/previous cohort. Cohort 5 will potentially explore additional dosing levels if sufficient data to identify the maximum tolerated dose (MTD) is not available with completion of Cohort 4. Treatment may continue for up to 24 cycles, unless discontinued earlier due to disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-specified criteria. Dosing of ZE74-0282 will be administered in a fasting state (i.e., at least 2 hours before and 1 hour after the dose no food or drink except for water).

Part 2: Once MTD has been determined in Part 1, then Part 2 will commence. Thirty participants will be dosed orally with ZE74-0282 across 2 dose cohorts. The doses used in Part 2 of the study will be determined based on the data from Part 1 of the study and will not exceed the MTD to further evaluate PK, PD, preliminary anti-leukemia activity of ZE74- 0282, and cumulative safety and tolerability data and to determine the recommended phase 2 dose (RP2D). Treatment may continue for up to 24 cycles, unless discontinued earlier due to disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-specified criteria. Dosing of ZE74-0282 will be administered in a fasting state (i.e., at least 2 hours before and 1 hour after the dose no food or drink except for water).

Adherence to the intervention will be managed via recording in appropriate drug accountability records.
Intervention code [1] 333744 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345029 0
Part 1 Primary Outcome: To determine the maximum tolerated dose (MTD) of ZE74-0282 in adults with selected V617F JAK2 mutated diseases.
Timepoint [1] 345029 0
DLT's will be documented daily from Cycle 1 Day 1 until Cycle 1 Day 28.
Primary outcome [2] 345299 0
Part 2 Primary Outcome: To determine the recommended phase 2 dose of ZE74-0282 in adults with selected V617F JAK2 mutated diseases.
Timepoint [2] 345299 0
Adverse Events (AE) will be graded using the most current version of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 5-point scale. Detection of treatment emergent adverse events (TEAE's) will be made by the Investigator using their clinical judgment as to the relationship between ZE74-0282 and the occurrence of each AE and will be rated as Unrelated or Related. Assessment extends from the signing of the consent form until completion of the last study-related procedure (including follow-up for safety assessments). Clinical laboratory parameters- Blood samples will be collected from Screening, Day -1, pre-dose Cycle 1 Day 1 - then 6 hrs post-dose, Day 2, Day 3, Day 15 and Day 28 post-dose, post-dose Day 1 of Cycle 2 - Cycle 5, then post-dose Day 1 of every 3rd Cycle until 4 - 6 weeks after last dose End of Study/Early Termination Visit (EOS/ETV). Clinical laboratory parameters- Urine samples will be collected from Screening, Day -1, pre-dose Cycle 1 Day 1 - then 6 hrs post-dose, Day 2 post-dose, Day 3 post-dose. ECG Parameters - 12-lead ECG recordings will be obtained in triplicate at Screening, Day -1, pre-dose Cycle 1 Day 1 - then 2 hr and 6 hrs post-dose, Day 2 post-dose, pre-dose on Day 8, 15 and Day 28, post-dose Day 1 of Cycle 2 - Cycle 5, then post-dose Day 1 of every 3rd Cycle until 4 - 6 weeks after last dose (EOS/ETV). Cycle 1 Blood plasma PK samples collected pre-dose Day 1 then 0.25, 0.5, 1, 0, 4 and 6 hrs post dose, pre-dose Day 2 and pre-dose Day 8. Cycle 2 Blood plasma PK samples collected pre-dose Day 1 then 0.25, 0.5, 1, 0, 4 and 6 hrs post dose and pre-dose Day 2. Blood plasma PD samples will be collected pre-dose Cycle 1 Day 1 then 6 hrs post-dose, pre-dose Day 8 and pre-dose Cycle 2 Day 1.
Secondary outcome [1] 460231 0
Composite Outcome: To describe the safety and tolerability profile of ZE74-0282.
Timepoint [1] 460231 0
Adverse Events (AE) will be graded using the most current version of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 5-point scale. Detection of TEAE's will be made by the Investigator using their clinical judgment as to the relationship between ZE74-0282 and the occurrence of each AE and will be rated as Unrelated or Related. Assessment extends from the signing of the consent form until completion of the last study-related procedure (including follow-up for safety assessments). Clinical laboratory parameters- Blood samples will be collected from Screening, Day -1, pre-dose Cycle 1 Day 1 - then 6 hrs post-dose, Day 2, Day 3, Day 15 and Day 28 post-dose, post-dose Day 1 of Cycle 2 - Cycle 5, then post-dose Day 1 of every 3rd Cycle until 4 - 6 weeks after last dose End of Study/Early Termination Visit (EOS/ETV). Clinical laboratory parameters- Urine samples will be collected from Screening, Day -1, pre-dose Cycle 1 Day 1 - then 6 hrs post-dose, Day 2 post-dose, Day 3 post-dose. ECG Parameters - 12-lead ECG recordings will be obtained in triplicate at Screening, Day -1, pre-dose Cycle 1 Day 1 - then 2 hr and 6 hrs post-dose, Day 2 post-dose, pre-dose on Day 8, 15 and Day 28, post-dose Day 1 of Cycle 2 - Cycle 5, then post-dose Day 1 of every 3rd Cycle until 4 - 6 weeks after last dose (EOS/ETV).
Secondary outcome [2] 460240 0
To characterize the plasma pharmacokinetic (PK) profile of ZE74-0282.
Timepoint [2] 460240 0
Cycle 1 Blood plasma samples collected pre-dose Day 1 then 0.25, 0.5, 1, 0, 4 and 6 hrs post dose, pre-dose Day 2 and pre-dose Day 8. Cycle 2 Blood plasma samples collected pre-dose Day 1 then 0.25, 0.5, 1, 0, 4 and 6 hrs post dose and pre-dose Day 2.
Secondary outcome [3] 460241 0
To assess additional parameters of preliminary antitumor activity of ZE74-0282 in patients treated. This will be assessed as a composite outcome.
Timepoint [3] 460241 0
Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) assessments of spleen and liver at Day 1 of Cycle 1, 2, 3, 6, 12 and 24. Blood samples will be collected from Screening, Day -1, pre-dose Cycle 1 Day 1 - then 6 hrs post-dose, Day 2, Day 3, Day 15 and Day 28 post-dose, post-dose Day 1 of Cycle 2 - Cycle 5, then post-dose Day 1 of every 3rd Cycle until 4 - 6 weeks after last dose End of Study/Early Termination Visit (EOS/ETV). MPN-SAF TSS will be completed pre-dose on Day 1 of each treatment cycle for the first three cycles, Day 1 of every 3rd cycle and then End of Study/Early Termination Visit (EOS/ETV).
Secondary outcome [4] 460242 0
To determine the proportion of patients who receive ZE74-0282 and go onto allogeneic stem cell transplant.
Timepoint [4] 460242 0
No pre-set timepoint, to be monitored on occurrence, cumulative data will be assessed at the conclusion of the study.

Eligibility
Key inclusion criteria
1. Patient is greater than or equal to 18 years of age at the time of obtaining informed consent.
2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
3. Patient has histological confirmation JAK2 V617F mutated hematologic diagnosis with later confirmation using ipsogen® JAK2 RGQ PCR Kit) with prior therapy or who have declined them. Specifics for disease include:
a. Myelofibrosis having received a JAK2 inhibitor or having declined it, spleen volume of 450 cm2 (by spleen or MRI) and TSS > 10 or 3 of 7 TSS scores >3
b. polycythemia vera with standard therapy having received hydroxyurea, ruxolitinib, and/or interferon (or declined it)
4. All AEs related to prior therapies (chemotherapy/systemic therapies, radiation, surgery) must have resolved to Grade 1 or baseline except for:
a. Alopecia (Grade less than or equal to 2)
b. Sensory neuropathy (Grade less than or equal to 2)
c. Other AEs that have resolved to Grade less than or equal to 2 that, according to the clinical judgment of
the investigator, do not constitute a safety risk to the patient.
5. Adequate hematologic function including
a. ANC greater than or equal to 1 x 109/L
b. Platelets greater than or equal to 50 x 109/L
c. Hemoglobin greater than or equal to 8 g/dl (80 g/L) (may be transfused)
6. Organ function/reserve as per the following laboratory criteria:
a. Hepatic: Aspartate aminotransferase (AST) less than or equal to 2.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) less than or equal to 2.5 x ULN, and total bilirubin < 2 x ULN (except for patients with known or suspected Gilbert’s syndrome and with direct bilirubin within normal range) for the local laboratory. If due to disease, higher values may be approved after discussion with medical monitor.
b. Renal: Adequate renal function as defined by calculated creatinine clearance >45 mL/min for the local laboratory.
7. Baseline corrected QT interval by Fredericia (QTcF) < 470 ms. Patients with right, left, or partial bundle branch blocks or pacemaker that may confound interpretation of this reading are not excluded from this provided they lack history of primary arrhythmic events and are cleared by cardiology for enrollment in the trial.
8. Pregnancy:
a. Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test result at screening (not applicable to patients who are unable to become pregnant, including those with bilateral oophorectomy and/or hysterectomy). The test must be performed within 72 hours before Day 1 of treatment.
b. Women of non-child-bearing potential must have at least 12 continuous months of natural (spontaneous) amenorrhea and an appropriate clinical profile (e.g., age appropriate or history of vasomotor symptoms) or have had surgical sterilization (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) >42 days prior to screening.
9. Contraception and Gamete Donation:
a. Male patients with a WOCBP partner must use 2 forms of acceptable contraception, including 1 barrier method, during their participation in the study and for 120 days following the last dose of the study treatment. They must also refrain from sperm donation from screening visit until 120 days following the last dose of study treatment.
b. Women of child-bearing potential must use 2 forms of acceptable contraception, including 1 barrier method, during their participation in the study and for 120 days following the last dose of the study treatment. They must also refrain from ova donation from screening visit until 120 days following the last dose of study treatment.
10. Written informed consent must be obtained according to local guidelines and signed and dated by the patient prior to the performance of any study specific procedures, sampling, or analyses.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Clinical signs or symptoms of leukostasis or thrombophilia requiring urgent therapy (e.g. leukapheresis).
2. Known active infection with HIV, hepatitis B, or hepatitis C, or uncontrolled infection requiring parenteral therapy.
3. Uncontrolled intercurrent illness, including but not limited to symptomatic congestive heart failure, unstable angina, serious cardiac arrhythmia, myocardial infarction with residual abnormalities, or stroke/transient ischaemic attack within 6 months prior to enrolment.
4. Receipt of systemic antineoplastic therapy, radiotherapy, or another investigational agent within 14 days prior to first ZE74-0282 dose, or planned participation in another investigational drug or device study.
5. Pregnant or breastfeeding women, or women planning pregnancy or breastfeeding during the study.
6. Active prior or concurrent malignancy that may interfere with the safety or efficacy assessment of ZE74-0282, except for malignancies with negligible risk (e.g. basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or early-stage prostate cancer on watchful waiting) or completely treated malignancy with no evidence of disease for greater than or equal to 2 years, if approved by the sponsor.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29391 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 45710 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 28019 0
Uzbekistan
State/province [1] 28019 0

Funding & Sponsors
Funding source category [1] 321580 0
Commercial sector/Industry
Name [1] 321580 0
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)
Country [1] 321580 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)
Address
Country
Australia
Secondary sponsor category [1] 324379 0
Commercial sector/Industry
Name [1] 324379 0
Avance Clinical Pty Ltd
Address [1] 324379 0
Country [1] 324379 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320109 0
Bellberry Human Research Ethics Committee C
Ethics committee address [1] 320109 0
Ethics committee country [1] 320109 0
Australia
Date submitted for ethics approval [1] 320109 0
08/04/2026
Approval date [1] 320109 0
Ethics approval number [1] 320109 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149462 0
Dr Carolyn Grove
Address 149462 0
Linear Clinical Research, B-Block, Hospital Avenue, Nedlands, Western Australia 6009
Country 149462 0
Australia
Phone 149462 0
+61 8 6383 4032
Fax 149462 0
Email 149462 0
Contact person for public queries
Name 149463 0
Carolyn Grove
Address 149463 0
Linear Clinical Research, B-Block, Hospital Avenue, Nedlands, Western Australia 6009
Country 149463 0
Australia
Phone 149463 0
+61 8 6382 5100
Fax 149463 0
Email 149463 0
Contact person for scientific queries
Name 149464 0
Carolyn Grove
Address 149464 0
Linear Clinical Research, B-Block, Hospital Avenue, Nedlands, Western Australia 6009
Country 149464 0
Australia
Phone 149464 0
+61 8 6382 5100
Fax 149464 0
Email 149464 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.